GALAPAGOS NV
GLPG3667
dermatomyositis (DM) and systemic lupus erythematosus (SLE)
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for GLPG3667 in dermatomyositis (DM) and systemic lupus erythematosus (SLE) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 14h ago
“Additionally, we continue to explore opportunities to expand into other severe autoimmune diseases with significant unmet medical need.”